A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Allergy and Clinical Immunology Associates, Pittsburgh

Novartis Investigative Site, Suwon

Novartis Investigative Site, Madrid

Novartis Investigative Site, Madrid

Novartis Investigative Site, Brest

Novartis Investigative Site, Hanover

Novartis Investigative Site, Toulouse

Florida Ctr Allergy Asthma Research, Aventura

Finlay Medical Research, Greenacres City

Novartis Investigative Site, Montpellier

Novartis Investigative Site, Marburg

Novartis Investigative Site, Izmir

Novartis Investigative Site, Göttingen

Novartis Investigative Site, Kayseri

Novartis Investigative Site, Daegu

Allergy and Asthma Specialist P S C, Owensboro

Novartis Investigative Site, Valencia

Novartis Investigative Site, Bramsche

Novartis Investigative Site, Angers

Novartis Investigative Site, Reims

Allergy Asthma and amp Sinus Ctr S C, Greenfield

Novartis Investigative Site, Samsun

Endeavor Health, Glenview

Acuro Research Inc, Little Rock

Allergy Asthma and Clinical Research, Oklahoma City

Novartis Investigative Site, Paris

Western Sky Medical Research, El Paso

Treasure Valley Medical Research, Boise

Novartis Investigative Site, Erlangen

Novartis Investigative Site, Antony

Novartis Investigative Site, Saint-Mandé

Novartis Investigative Site, Singapore

Novartis Investigative Site, Nueve de Julio

Novartis Investigative Site, Sourigues

Novartis Investigative Site, Santa Fe

Novartis Investigative Site, Rosario

Novartis Investigative Site, Calgary

Novartis Investigative Site, Montreal

Novartis Investigative Site, Halle

Novartis Investigative Site, Komárno

Novartis Investigative Site, Levice

Novartis Investigative Site, Nové Zámky

Novartis Investigative Site, Seoul

Novartis Investigative Site, Alicante